Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

EpiSwitch™ captures the heterogeneity of the environment on the genome.

Our Publications on Episwitch™


Ectopic gene deregulations and chromosome conformations: integrating novel molecular testing into clinical applications, from leukemias to gliomas

Handbook of Biomarkers and Precision Medicine
https://www.crcpress.com/Handbook-of-Biomarkers-and-Precision-Medicine/Carini-Fidock-Gool/p/book/9781498762588

Epigenetic chromatin conformation changes in peripheral blood can detect thyroid cancer.

Yan et. al.,
Surgery
https://doi.org/10.1016/j.surg.2018.05.081

Genomic architecture differences at the HTT locus underlie symptomatic and pre-symptomatic cases of Huntington’s disease.

Salter, M., et. al.,
F1000Research 2018, 7:1757
https://doi.org/10.12688/f1000research.15828.1

The Chromosomal Conformation Signature: A New Kid on the Block in ALS Biomarker Research?

Poesen, K.
EBioMedicine
https://doi.org/10.1016/j.ebiom.2018.06.015